HOYA Corporation 7741.T JPX · Healthcare · Japan
¥23,095.00 -2.02% -¥475.00
Summary
81 / 100 · Bulios Score
What speaks for it
- Out of every 100 JPY of revenue, 28 JPY is left as net profit.
- It earns 22 JPY a year on every 100 JPY of invested capital.
- Earnings per share grew by 17% a year over the last 3 years.
- It holds more cash than debt: ¥561.9B against ¥42.2B.
What to watch
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBy our assumptions the price matches the value of the business: the two differ by less than 10 %.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 27.9 JPY for 1 JPY of yearly profit. Over the last five years it was 32.7 JPY on average.
Valuation in detailIs it growing?
Yes, fastRevenue (JPY)
Diluted EPS (JPY)
- Analyst estimate
Revenue grew by 12% a year over 5 years. Over the last 3 years it grew by 9.4% a year. For the next fiscal year analysts expect revenue to grow by 11%. Earnings per share grew by 17% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 JPY of revenue goes
- Cost of sales 22 JPY
- Research and development 1.8 JPY
- Sales and administration 46 JPY
- Taxes and other 3.1 JPY
- Net profit 28 JPY
Net profit, industry median (Medical - Instruments & Supplies) 8.5 JPY
Out of every 100 JPY of revenue, 28 JPY is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 0.55%
- Paid out of profit
- 15%
You receive ¥130.00 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail